AbbVievs.Merck & Co.
ABBV vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 1.4× larger than Merck & Co. by market cap; AbbVie trades at the lower P/E (76.0 vs 109.9); year to date, Merck & Co. leads (+35.7% vs +18.8%).
Side by side
| ABBV | MRK | |
|---|---|---|
| Market cap | $480B | $349B |
| Price | $272.42 | $142.38 |
| Today | +0.4% | −0.3% |
| Return YTD | +18.8% | +35.7% |
| Return 1Y | +16.5% | +63.0% |
| Since June 26, 2026 | +7.5% | +10.7% |
| P/E | 76.0 | 109.9 |
| P/S | 7.4 | 5.2 |
| P/B | 337.7 | 8.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →Merck & Co.MRK
Keytruda is the centre of the oncology business, which sits next to a substantial vaccines portfolio. Animal health forms a third division.
Full MRK profile →More ABBV & MRK comparisons
Other head-to-heads in the Big pharma segment.